icon-folder.gif   Conference Reports for NATAP  
  The Liver Meeting
Washington DC
October 2017
Back grey_arrow_rt.gif
The incidence of hepatocellular carcinoma is not increased after DAA therapy
  Reported by Jules Levin
AASLD: The Liver Meeting 2017, October 20-24, 2017, Washington, DC
Darrick K. Li MD, PhD1, Yanjie Ren MS2, Daniel S. Fierer MD3, Stephanie Rutledge MD1, Obaid S. Shaikh MD2, Vincent Lo Re III MD, MSCE4, Tracey Simon MD1, Abdul-Badi Abou-Samra MD, PhD5,6, Raymond T. Chung MD1*, Adeel A. Butt MD, MS2,5,6
1 Massachusetts General Hospital, Boston, MA; 2 VA Pittsburgh Healthcare System, Pittsburgh, PA; 3 Icahn School of Medicine at Mount Sinai, New York, NY; 4 Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; 5 Hamad Medical Corporation, Doha, Qatar; 6 Weill Cornell Medical College, Doha, Qatar and New York, NY


Recurrent HCC has been reported in some but not all studies. We took this approach as we believe that de novo occurrence is the more clinically relevant issue and that the risk of recurrence following HCC will be higher than the de novo rate regardless of HCV treatment type.